Colin Minchom, PhD
Colin Minchom PhD FRPharmS has over thirty year’s experience in CMC leadership, drug product formulation & drug delivery for all stages of the development continuum. Prior to joining Delix he consulted to startup and Pharma companies for six years and was previously at Shire Pharmaceuticals as the CMC lead for two priority rare disease programs, where he was also the head of CMC Due Diligence for synthetic molecules. Dr. Minchom worked in contract services for fourteen years latterly holding executive leadership positions at Patheon leading drug product development services for North America, and Hovione where he led the teams improving bioavailability of poorly soluble molecules. He previously worked at Eli Lilly at the discovery/development interface, and also a UK CNS startup.
Dr. Minchom is a life science mentor at MassBioDrive, the Massbio entrepreneur mentorship program and is a member of the American Association of Pharmaceutical Scientists, for which he chaired the science committee for the AAPS 25th anniversary annual meeting.
He was vice-chair of the USP General Chapters Expert Committee for dosage forms, has lectured at Harvard Medical School, and presented at an MIT conference on enabling drug delivery technologies. Trained as a pharmacist, Dr. Minchom received his PhD in Pharmaceutics from the University of Wales, UK and is a Fellow of the Royal Pharmaceutical Society of Great Britain.